The study centers on the sigma-1 receptor, or S1R, an endoplasmic reticulum chaperone protein that is abundantly expressed throughout the brain. Unlike classical neurotransmitter receptors, S1R functions as a molecular chaperone, physically interacting with a wide range of client proteins and modulating their behavior at the cell surface. Intriguingly, many conventional antidepressants bind to S1R with moderate to high affinity. Fluoxetine, better known as Prozac, shows an affinity of roughly 191 nanomolar for the receptor, and clinical pharmacokinetic data indicate that therapeutic blood concentrations of the drug range from 200 nanomolar to 3 micromolar, well within the range needed to engage S1R meaningfully.

Previous work had suggested that S1R ligands can produce antidepressant-like effects in preclinical models within approximately three days, far faster than the weeks required for conventional agents. The critical question was why. If fluoxetine and other SSRIs already touch the sigma-1 receptor, why do they act slowly while selective S1R agonists act quickly? Ren and colleagues hypothesized that the answer lies in a physical complex formed between S1R and the serotonin 1A receptor, or 5-HT1AR, a G protein-coupled receptor that normally exerts inhibitory control over serotonergic neurons in the dorsal raphe nucleus, the brain’s principal source of serotonin.

To test this idea, the team deployed an unusually comprehensive experimental arsenal. Double immunofluorescence staining revealed that S1R and 5-HT1AR are co-expressed in the dorsal hippocampal CA3 region, the medial prefrontal cortex, and the dorsal raphe nucleus of the mouse brain. Co-immunoprecipitation confirmed a physical interaction between the two proteins, and an in-situ proximity ligation assay, which generates fluorescent signals only when two proteins sit within 40 nanometers of each other, demonstrated that the heterocomplex forms primarily at the plasma membrane, with the strongest signal detected in the dorsal raphe nucleus. Microscale thermophoresis measurements using recombinant proteins quantified the interaction at a binding affinity of 2.62 micromolar.

The functional consequences of this partnership proved striking. When the researchers treated cells with SA-4503, a classic selective S1R agonist, total protein levels of both receptors remained unchanged, but their abundance at the plasma membrane increased significantly, indicating that S1R activation drives both receptors toward the cell surface. FRET analysis, which detects molecular proximity within 10 nanometers, confirmed a specific interaction between fluorescently tagged S1R and 5-HT1AR, and this signal was disrupted by antagonists of either receptor. Most importantly, in a CREB luciferase reporter assay, a high concentration of SA-4503 reversed the suppressive effect of the 5-HT1AR agonist 8-OH-DPAT on forskolin-stimulated CREB signaling, suggesting that the heterocomplex allosterically rewires 5-HT1AR’s canonical inhibitory pathway.

Behavioral experiments in mice subjected to chronic restraint stress, a widely used depression model involving six hours of daily confinement for 21 consecutive days, provided the translational link. Three days of SA-4503 treatment restored sucrose preference to control levels and reduced immobility in both the tail suspension and forced swim tests, effects that were abolished by co-administration of either the S1R antagonist NE-100 or the 5-HT1AR antagonist WAY-100635. Crucially, the levels of the S1R/5-HT1AR heterocomplex in dorsal raphe serotonergic neurons, measured by proximity ligation assay, were reduced in stressed mice and restored by SA-4503, and correlated positively with sucrose preference, tying the molecular complex directly to depression-related behavior.

To establish causality rather than mere correlation, the team engineered cell-penetrating interference peptides based on the transmembrane domains of 5-HT1AR. Molecular docking and mass spectrometry identified transmembrane domains 2 and 7 as the primary dimerization interfaces. When these TAT-TM peptides were infused into the brain ventricles, they disrupted heterocomplex formation in the dorsal raphe and abolished SA-4503’s rapid antidepressant-like effects across behavioral tests. The peptides also prevented the drug-induced increases in phosphorylated ERK1/2 and brain-derived neurotrophic factor in the medial prefrontal cortex, and reversed the enhancement of dendritic spine density on prefrontal pyramidal neurons, linking the heterocomplex to the synaptic plasticity machinery long associated with sustained antidepressant action.

Electrophysiology then revealed where and how the complex acts. In serotonergic neurons of the dorsal raphe nucleus, activation of 5-HT1AR opens G protein-coupled inwardly rectifying potassium channels, hyperpolarizing the cells and suppressing their firing. Co-application of SA-4503 with 8-OH-DPAT significantly attenuated this potassium current and restored neuronal excitability, and the TM2 peptide abolished this rescue. Notably, S1R activation did not directly alter the intrinsic excitability of prefrontal pyramidal neurons; instead, it prevented the excessive hyperpolarization that 5-HT1AR activation would otherwise impose. The primary locus of action thus appears to be the dorsal raphe, where the heterocomplex functions as a kind of autoregulatory brake-release mechanism on the brain’s serotonin supply.

The circuit-level story was completed with viral tracing, fiber photometry, and chemogenetics. The researchers confirmed that dorsal raphe serotonergic neurons make monosynaptic excitatory connections onto pyramidal neurons in the medial prefrontal cortex, a region the same group previously identified as a rate-limiting step for antidepressant efficacy. Disrupting the heterocomplex within the dorsal raphe reduced calcium activity in prefrontal projection neurons and induced depressive-like behavior in otherwise healthy mice. Conversely, chemogenetic activation of the raphe-to-prefrontal pathway with a DREADD agonist reversed those behaviors. The authors propose that this mechanism also explains the delayed onset of SSRIs: fluoxetine rapidly elevates serotonin, which initially activates inhibitory autoreceptors and suppresses raphe firing, while its weaker S1R activity only gradually builds enough heterocomplex density to overcome that brake. The work remains entirely preclinical, and the authors note that only male mice were studied, but it identifies the S1R/5-HT1AR heterocomplex as a concrete molecular target for designing antidepressants that work in days rather than weeks.

Subject of Research: Sigma-1 receptor and serotonin 1A receptor heterocomplex mediation of faster-onset antidepressant effects via the dorsal raphe nucleus to medial prefrontal cortex circuit

Article Title: Sigma-1 receptor activation mediates a faster antidepressant-like effect through disinhibition of the DRN 5-HT -mPFC pyr neural circuit via S1R/5-HT 1A R heterocomplex

Article References: Ren, P., Wang, J.-Y., Yan, J.-Z., Chen, H.-L., Duan, J.-Y., Xu, M.-J., Cui, L.-Y., Zhang, L.-M., & Li, Y.-F. (2026). Sigma-1 receptor activation mediates a faster antidepressant-like effect through disinhibition of the DRN5-HT-mPFCpyr neural circuit via S1R/5-HT1AR heterocomplex. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.10.031

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.10.031

Keywords: sigma-1 receptor, 5-HT1A receptor, heterocomplex, dorsal raphe nucleus, medial prefrontal cortex, antidepressant onset, major depressive disorder, SSRIs, GIRK channels, serotonin neurons, chronic restraint stress, neuroplasticity